canonical Wnt/β-catenin signaling

Pathways Recommended:	Stem Cell/Wnt Neuronal Signaling JAK/STAT Signaling

By Targets:	Wnt (15) β-catenin (7) Androgen Receptor (1) Apoptosis (1) CDK (1) DNA/RNA Synthesis (1) Na+/H+ Exchanger (NHE) (1) Organoid (2) PARP (1) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (2)

Targets Recommended: β-catenin Wnt RGS Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12238

IWR-1 Maximum Cited Publications 61 Publications Verification endo-IWR 1; IWR-1-endo	Organoid Wnt	Inflammation/Immunology Cancer
IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting *Wnt/β-catenin* (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical **Wnt signaling*, namely translocation of β-catenin* to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

HY-P1416

Foxy-5 5+ Cited Publications	Wnt	Cancer
Foxy-5, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-13815

KY02111 5 Publications Verification	Wnt	Cardiovascular Disease
KY02111 is a canonical **WNT signaling (β-catenin)** inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .

HY-108442

JW67 1 Publications Verification	Wnt	Cancer
JW67 inhibits the canonical *Wnt* signaling with an IC₅₀ of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of *Wnt* target genes. JW67 also inhibits colorectal cancer cell growth .

HY-P1416A

Foxy-5 TFA 5+ Cited Publications	Wnt	Cancer
Foxy-5 TFA, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-117233

UU-T02 1 Publications Verification	β-catenin Wnt	Metabolic Disease Cancer
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction *(β-catenin/Tcf PPI)* with a K_i of 1.36 μM . UU-T02 inhibits canonical *Wnt* signaling and the growth of colorectal cancer cells .

HY-115543

β-catenin-IN-37	Wnt β-catenin	Cancer
β-catenin-IN-37 is a selective β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively .

HY-12238G

IWR-1 endo-IWR 1; IWR-1-endo	Organoid Wnt	Inflammation/Immunology Cancer
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting *Wnt/β-catenin* (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical **Wnt signaling*, namely translocation of β-catenin* to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

HY-N7702

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide 1 Publications Verification	Wnt β-catenin	Metabolic Disease
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical *Wnt/β‐catenin* signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis .

HY-108442R

JW67 (Standard)	Reference Standards Wnt	Cancer
JW67 (Standard) is the analytical standard of JW67 (HY-108442). This product is intended for research and analytical applications. JW67 inhibits the canonical Wnt signaling with an IC₅₀ of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth .

HY-P11867

UM206_L	Wnt β-catenin	Others
UM206_L is a linear *Wnt* fragment peptide derived from conserved *Wnt3a/Wnt5a* sequences, inactive in soluble form but capable of activating canonical *Wnt/β-catenin* signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .

HY-P11867A

UM206_C	Wnt β-catenin	Others
UM206_C is a circular *Wnt* fragment peptide derived from conserved *Wnt3a/Wnt5a* sequences, inactive in soluble form but capable of activating canonical *Wnt/β-catenin* signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .

HY-182624

FJ9	Na+/H+ Exchanger (NHE) Wnt Apoptosis	Cancer
FJ9 is a NHERF1/PDZ inhibitor with human NHERF1 PDZ1 IC₅₀ 1540 μM, NHERF1 PDZ2 IC₅₀ 160 μM, and Frizzled-7-Dishevelled PDZ complex K_i 10 μM. FJ9 binds ligand-binding pockets of NHERF1 PDZ domains to block cognate ligand interactions, disrupts Frizzled-7-Dishevelled interactions, and down-regulates canonical *Wnt* signaling. FJ9 induces apoptosis in cancer cells with intact β-catenin signaling. FJ9 can be used for the research of non-small cell lung cancer, melanoma .

HY-181999

PC8	PARP CDK Protease Activated Receptor (PAR) Wnt β-catenin Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cancer
PC8 is a selective dual inhibitor of PARP1/CDK6, with an IC₅₀ of 0.126 μM for PARP1 and 0.197 μM for CDK6. PC8 does not alter PARP1 expression, but reduces the expression of its downstream target PAR. PC8 inhibits the canonical *Wnt/β-catenin* signaling pathway. PC8 induces intracellular ROS accumulation and exacerbates DNA damage. PC8 inhibits the proliferation of triple-negative breast cancer (TNBC) cells. PC8 can be used for the research of triple-negative breast cancer .

HY-P11660

β-catenin-IN-10	β-catenin Wnt Androgen Receptor	Cancer
β-catenin-IN-10 is a β-catenin:TCF4 interaction inhibitor with an IC₅₀ of 5.44 μM. β-catenin-IN-10 inhibits the Wnt and AR signaling pathways with IC₅₀ values of 0.105 μM and 1.02 μM, respectively. β-catenin-IN-10 suppresses the proliferation of castration-resistant prostate cancer cells. β-catenin-IN-10 is applicable to research related to prostate cancer .

Cat. No.	Product Name	Type

HY-12238G

IWR-1 endo-IWR 1; IWR-1-endo	Fluorescent Dyes
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting *Wnt/β-catenin* (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical **Wnt signaling*, namely translocation of β-catenin* to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

IWR-1

endo-IWR 1; IWR-1-endo

Fluorescent Dyes

IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

Cat. No.	Product Name	Type

HY-12238G

IWR-1 endo-IWR 1; IWR-1-endo	Biochemical Assay Reagents
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting *Wnt/β-catenin* (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical **Wnt signaling*, namely translocation of β-catenin* to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

IWR-1

endo-IWR 1; IWR-1-endo

Biochemical Assay Reagents

IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

Cat. No.	Product Name	Target	Research Area

HY-P1416

Foxy-5 5+ Cited Publications	Wnt	Cancer
Foxy-5, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1416A

Foxy-5 TFA 5+ Cited Publications	Wnt	Cancer
Foxy-5 TFA, a *WNT5A* agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P11867

UM206_L	Wnt β-catenin	Others
UM206_L is a linear *Wnt* fragment peptide derived from conserved *Wnt3a/Wnt5a* sequences, inactive in soluble form but capable of activating canonical *Wnt/β-catenin* signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .

HY-P11867A

UM206_C	Wnt β-catenin	Others
UM206_C is a circular *Wnt* fragment peptide derived from conserved *Wnt3a/Wnt5a* sequences, inactive in soluble form but capable of activating canonical *Wnt/β-catenin* signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces .

HY-P11660

β-catenin-IN-10	β-catenin Wnt Androgen Receptor	Cancer
β-catenin-IN-10 is a β-catenin:TCF4 interaction inhibitor with an IC₅₀ of 5.44 μM. β-catenin-IN-10 inhibits the Wnt and AR signaling pathways with IC₅₀ values of 0.105 μM and 1.02 μM, respectively. β-catenin-IN-10 suppresses the proliferation of castration-resistant prostate cancer cells. β-catenin-IN-10 is applicable to research related to prostate cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7702

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide 1 Publications Verification	Natural Products other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	Wnt β-catenin
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical *Wnt/β‐catenin* signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis .

Targets Recommended: β-catenin Wnt RGS Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12238G

IWR-1 endo-IWR 1; IWR-1-endo	Organoid Wnt	Inflammation/Immunology Cancer
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting *Wnt/β-catenin* (IC₅₀ = 180 nM). IWR-1 compromises critical steps of the canonical **Wnt signaling*, namely translocation of β-catenin* to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

GMP Molecules

Name
Email *

	Sorry, but the email address you supplied was invalid.

canonical Wnt/β-catenin signaling

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

GMP Molecules

Natural
Products